Trials / Completed
CompletedNCT05805904
A Study to Evaluate the Drug Levels, Safety, and Tolerability of BMS-986278 in Healthy Chinese Participants
A Double-blind, Placebo-controlled, Randomized, Single and Multiple Dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of BMS-986278 in Healthy Chinese Participants
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 24 (actual)
- Sponsor
- Bristol-Myers Squibb · Industry
- Sex
- All
- Age
- 21 Years – 65 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to evaluate the drug levels, safety, and tolerability of BMS-986278 in healthy Chinese participants.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BMS-986278 | Specified dose on specified days. |
| DRUG | Placebo | Specified dose on specified days |
Timeline
- Start date
- 2023-03-29
- Primary completion
- 2023-05-23
- Completion
- 2023-05-23
- First posted
- 2023-04-10
- Last updated
- 2023-09-18
Locations
1 site across 1 country: China
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05805904. Inclusion in this directory is not an endorsement.